Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A. Walker, Gareth J. Morgan, Lauren I. Aronson et al.|Journal of Clinical Oncology|2015Cited by 564
Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemiaMartin Kaiser, Claudia D. Baldus|Blood Cancer Journal|2011Cited by 74
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Matthew Jenner, Charlotte Pawlyn et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 22
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Kwee Yong, Samantha Hinsley et al.|BMC Hematology|2016Cited by 9
Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior RegimenKwee Yong, Catherine Williams, Sarah Brown et al.|Blood|2015Cited by 6